209 related articles for article (PubMed ID: 17631604)
1. Renal cell cancer: is immunotherapy dead?
Wagstaff J
Ann Oncol; 2007 Jul; 18 Suppl 9():ix94-7. PubMed ID: 17631604
[No Abstract] [Full Text] [Related]
2. Immunotherapeutic approaches for renal cancer.
Pizza G; de Vinci C; Viza D
Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765
[No Abstract] [Full Text] [Related]
3. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
4. Biologic response modifiers in the therapy of metastatic renal cell carcinoma.
Quesada JR
Semin Oncol; 1988 Aug; 15(4):396-407. PubMed ID: 2457256
[No Abstract] [Full Text] [Related]
5. Immunotherapy for renal carcinoma: theoretical basis and current standard of care.
Vasey PA
Br J Clin Pharmacol; 2000 Dec; 50(6):521-9. PubMed ID: 11136291
[No Abstract] [Full Text] [Related]
6. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
7. Metastatic renal cell carcinoma: systemic treatment.
Abi-Aad AS; deKernion JB
Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
[No Abstract] [Full Text] [Related]
8. Renal cell carcinoma and interleukin-2: a review.
Wagstaff J; Baars JW; Wolbink GJ; Hoekman K; Eerenberg-Belmer AJ; Hack CE
Eur J Cancer; 1995; 31A(3):401-8. PubMed ID: 7540404
[No Abstract] [Full Text] [Related]
9. Combination immunotherapy in renal cell carcinoma.
Drake CG
Clin Adv Hematol Oncol; 2016 Feb; 14(2):99-100. PubMed ID: 27057808
[No Abstract] [Full Text] [Related]
10. Eosinophilia induced by interleukin-2 cancer immunotherapy may be associated with enhanced production of total IgE.
Vecchi L; Lissoni P
Int J Biol Markers; 1995; 10(1):59-60. PubMed ID: 7629429
[No Abstract] [Full Text] [Related]
11. Immunotherapy for renal cell cancer.
Bower M; Roylance R; Waxman J
QJM; 1998 Sep; 91(9):597-602. PubMed ID: 10024913
[No Abstract] [Full Text] [Related]
12. Immunotherapy of metastatic renal cell cancer.
Fishman M; Seigne J
Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for renal cell cancer.
Yang JC; Childs R
J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
[TBL] [Abstract][Full Text] [Related]
14. Renal cancer immunotherapy: a ray of hope or regression to the mean?
Stadler W
Cancer Invest; 2000; 18(5):490-1. PubMed ID: 10834033
[No Abstract] [Full Text] [Related]
15. [The immunotherapy of advanced renal cell carcinoma].
Bergmann L; Weidmann E; Mitrou PS
Dtsch Med Wochenschr; 1991 Mar; 116(10):384-90. PubMed ID: 1705879
[No Abstract] [Full Text] [Related]
16. Immunotherapy for renal cell carcinoma.
Rosenblatt J; McDermott DF
Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for metastatic renal cell carcinoma.
McDermott DF; Rini BI
BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
[No Abstract] [Full Text] [Related]
18. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.
Leppert JT; Lam JS; Belldegrun AS
J Immunother; 2005; 28(5):427-9. PubMed ID: 16113598
[No Abstract] [Full Text] [Related]
19. 5T4 as a target for immunotherapy in renal cell carcinoma.
Elkord E; Shablak A; Stern PL; Hawkins RE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1705-9. PubMed ID: 19954280
[No Abstract] [Full Text] [Related]
20. New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer.
Oliver RT
Eur J Cancer; 1991; 27(9):1168-72. PubMed ID: 1835631
[No Abstract] [Full Text] [Related]
[Next] [New Search]
